SEC Comment Letter 0000000000-25-009420 to 216 Pharmacy Corp (CIK 0002082327)
216 Pharmacy Corp (CIK 0002082327)
Date: Sept. 2, 2025 · CIK: 0002082327 · Accession: 0000000000-25-009420
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12651
Letter
Re: 216 Pharmacy Corp Offering Statement on Form 1-A Filed August 25, 2025 File No. 024-12651 Dear Danny Williamson:
September 2, 2025
Danny Williamson CEO, President and Director 216 Pharmacy Corp 4400 N. Scottsdale Rd. Ste 984 Scottsdale, AZ 85251
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. In connection with your request, please confirm in writing that at least one state has advised you that it is prepared to qualify or register your offering. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.
We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Rebekah Reed at 202-551-5332 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Trade &
Services
cc: Matt Stout
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 2, 2025 Danny Williamson CEO, President and Director 216 Pharmacy Corp 4400 N. Scottsdale Rd. Ste 984 Scottsdale, AZ 85251 Re: 216 Pharmacy Corp Offering Statement on Form 1-A Filed August 25, 2025 File No. 024-12651 Dear Danny Williamson: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. In connection with your request, please confirm in writing that at least one state has advised you that it is prepared to qualify or register your offering. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Rebekah Reed at 202-551-5332 with any questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc: Matt Stout </TEXT> </DOCUMENT>